INmune Bio, Inc. INMB
- Market cap
- $55.5M
- P/E
- 0.0×
Follow INMB
Target Price Range
Analyst price targets
Free account| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | 3.51 | 2.20 | 9.23 | 4.63 | 5.87 | 4.32 | 1.38 |
Analyst estimates 2026–2028 Powerpack |
Low Price
|
||
| — | — | — | 11.50 | 24.42 | 30.37 | 11.78 | 11.78 | 14.74 | 11.64 |
High Price
|
|||
| — | 2 | 3 | 4 | 5 | 10 | 10 | 17 | 22 | 21 |
Employees
|
|||
| — | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Revenue/Emp
|
|||
| — | — | — | — | 0 | 0 | 0 | 0 | 0 | 0 |
Revenue
|
|||
| — | — | — | — | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
Gross Margin
|
|||
| 0 | (1) | (12) | (8) | (12) | (30) | (27) | (30) | (42) | (46) |
EBT
|
|||
| 0.00% | 0.00% | 0.00% | 0.00% | (109,990.91%) | (16,762.43%) | (7,299.20%) | (19,360.00%) | (300,685.71%) | (91,866.00%) |
EBT Margin
|
|||
| 0 | (1) | (12) | (8) | (12) | (30) | (27) | (30) | (42) | (46) |
Net Income
|
|||
| — | — | — | — | — | 0 | 0 | 0 | 0 | 0 |
Depreciation
|
|||
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.02 | 0.01 | 0.00 | 0.00 |
Revenue/Sh
|
|||
| (0.02) | (0.13) | (1.43) | (0.75) | (1.01) | (1.88) | (1.52) | (1.67) | (2.11) | (1.86) |
Earnings/Sh
|
|||
| (0.03) | (0.12) | (0.24) | (0.52) | (0.75) | (1.77) | (1.27) | (0.67) | (1.67) | (0.91) |
Cash Flow/Sh
|
|||
| 0.00 | (0.02) | 0.00 | 0.00 | 0.00 | (0.93) | 0.00 | 0.00 | 0.00 | (0.04) |
Capex/Sh
|
|||
| (0.03) | (0.13) | (0.24) | (0.52) | (0.75) | (2.70) | (1.27) | (0.67) | (1.67) | (0.95) |
Free CF/Sh
|
|||
| (0.01) | 2.76 | 1.91 | 2.30 | 3.23 | 4.97 | 3.35 | 2.08 | 1.61 | 0.95 |
Book Value/Sh
|
|||
| 11 | 7 | 9 | 10 | 12 | 16 | 18 | 18 | 20 | 25 |
Shares
|
|||
| — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
PE Ratio
|
|||
| — | — | — | — | 0.00 | 857.41 | 321.63 | 1,301.59 | 710.98 | 286.09 |
PS Ratio
|
|||
| — | — | — | — | 5.33 | 2.05 | 2.00 | 5.40 | 2.90 | 1.64 |
PB Ratio
|
|||
| — | — | — | — | 0.00 | 543.28 | 221.48 | 1,149.65 | 588.45 | 138.83 |
EV/Sales
|
|||
| — | — | — | — | (20.64) | (3.66) | (3.65) | (14.87) | (2.31) | (0.79) |
EV/FCF
|
|||
| 0 | (1) | (2) | (5) | (9) | (29) | (23) | (12) | (33) | (23) |
Op' Cash Flow
|
|||
| — | 0 | — | — | — | (15) | — | — | — | (1) |
Capex
|
|||
| 0 | (1) | (2) | (5) | (9) | (44) | (23) | (12) | (33) | (24) |
FCF
|
|||
| 0 | 2 | 0 | 7 | 22 | 78 | 54 | 21 | 15 | 21 |
Working Cap'
|
|||
| 0 | — | — | 0 | 0 | 15 | 15 | 10 | — | — |
Total Debt
|
|||
| 0 | (1) | 0 | (7) | (22) | (60) | (37) | (26) | (21) | (25) |
Net Debt
|
|||
| 0 | 18 | 17 | 24 | 39 | 80 | 60 | 37 | 32 | 24 |
Sh' Equity
|
|||
| (2.94%) | (8.82%) | (69.54%) | (36.71%) | (37.16%) | (43.16%) | (30.04%) | (43.24%) | (87.16%) | (127.75%) |
ROA
|
|||
| 0.00% | (3.67%) | (47.54%) | (28.88%) | (45.10%) | (91.35%) | (71.62%) | (162.87%) | (238.53%) | 0.00% |
ROIC
|
|||
| (3.09%) | (9.26%) | (71.82%) | (38.25%) | (38.80%) | (51.00%) | (38.91%) | (61.59%) | (121.21%) | (165.16%) |
ROE
|
|||
INmune Bio, Inc. peers in Biotechnology
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| MREO Mereo BioPharma Group plc - Sponsored ADR | $54.9M | 0.0× | Compare |
| EDSA Edesa Biotech, Inc. | $54.5M | 0.0× | Compare |
| SER Serina Therapeutics, Inc. | $54.4M | 0.0× | Compare |
| ANVS Annovis Bio, Inc. | $56.8M | 0.0× | Compare |
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| LONA LeonaBio, Inc. | $54.3M | 0.0× | Compare |
| HRTX Heron Therapeutics, Inc. | $57.0M | 0.0× | Compare |
| EXOZ eXoZymes Inc. | $57.6M | 0.0× | Compare |
| ELTX Elicio Therapeutics, Inc. | $53.4M | 0.0× | Compare |
INmune Bio, Inc. (INMB) key facts
- INmune Bio, Inc. (INMB) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- INmune Bio, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $50,000.00, up 257.1% from fiscal 2024.
- As of September 25, 2026, INMB traded at $2.03, a market capitalization of $55.5 million.
- Return on equity was −165.2% and debt-to-equity 0.00.
INmune Bio, Inc. (INMB) Latest News
14 Sep
INmune Bio appoints Sanofi rare-disease executive and biopharma business development leader to board. Board additions from Sanofi bring rare-disease and business development expertise that moderately strengthens leadership and strategy.
26 Aug
INmune Bio files regulatory documents with EMA to advance Ebstrocel™ toward European marketing authorization. EMA regulatory filings represent major step toward European product approval that can significantly shift INmune Bio trajectory and investor sentiment.
7 Aug
INmune Bio Inc secured regulatory wins and outlined strategic priorities during its Q2 2026 earnings call. Regulatory wins can accelerate drug approvals and reshape INmune Bio's development timeline and market position.
INmune Bio, Inc. (INMB) released its Q2 2026 earnings call transcript covering financial results and operational updates. Quarterly earnings calls typically drive moderate short-term shifts in valuation and investor views for the company.
INmune Bio, Inc. conducted its Q2 2026 earnings call covering financial results, operational updates, and forward outlook. Quarterly earnings call supplies performance data and guidance that can shift near-term investor views without guaranteeing structural change.
6 Aug
INmune Bio Inc. announced second quarter 2026 results and updated on regulatory, manufacturing and clinical progress. Regulatory, manufacturing and clinical progress updates signal major strategic advances likely to shift company trajectory and investor sentiment.
INmune Bio held its Q2 earnings call covering financial results, clinical progress on drug candidates, cash position, and upcoming milestones in its immunotherapy pipeline. Quarterly earnings updates supply performance data and pipeline status that moderately affect near-term stock sentiment and valuation.
20 Jul
INmune Bio completed commercial manufacturing milestone for CORDStrom platform supporting planned global registration filings. Manufacturing milestone completion advances CORDStrom toward global regulatory submissions and commercialization.
15 Jul
INmune Bio’s XPro1595 prevents brain-injury-induced Alzheimer's pathology, memory loss, and pain in a new peer-reviewed preclinical study. Positive preclinical data on XPro1595 may lift short-term sentiment and support pipeline visibility without altering company trajectory.
9 Jul
INmune Bio will present positive Phase 2 imaging data for XPro in early Alzheimer’s disease at the AAIC conference. Positive Phase 2 data presentation for lead Alzheimer’s candidate at major conference is likely to drive significant investor interest and advance development trajectory.
1 Jul
INmune Bio advances CORDStrom platform patent application in the U.S. after favorable international written opinion. Patent progress strengthens IP protection for CORDStrom platform supporting product development and positioning.
25 Jun
INmune Bio Inc. secured MHRA approval of its Paediatric Investigation Plan for CORDStrom™. MHRA PIP approval marks key regulatory advance for CORDStrom development.
23 Jun
INmune Bio secured MHRA written alignment supporting its planned 2026 UK Conditional Marketing Authorization Application for CORDStrom™ in RDEB. MHRA alignment advances CORDStrom™ toward UK conditional approval and commercialization.
2 Jun
INmune Bio reports statistically significant treatment effect on advanced white matter MRI biomarker in Phase 2 MINDFuL Alzheimer's trial. Positive Phase 2 Alzheimer's biomarker data signals major upside for drug development and stock performance.
1 Jun
INmune Bio released its Q4 2025 earnings transcript detailing financial results, operational updates, and future outlook for the company. Earnings transcript contains forward-looking statements and financial metrics that typically drive stock price and investor sentiment.
15 May
INmune Bio publishes Phase 2 MINDFuL trial results for XPro™ in NPJ Dementia, advancing the platform toward Alzheimer's treatment. Phase 2 trial publication in peer-reviewed journal signals clinical progress, boosting INMB's pipeline credibility and investor sentiment.
14 May
INmune Bio, Inc. (INMB) receives FDA Fast Track Designation for XPro1595 in early Alzheimer's Disease, accelerating development and review of the therapy targeting neuroinflammation. FDA Fast Track Designation for XPro1595 speeds up Alzheimer's development, de-risks the pipeline, and likely boosts INMB's investor sentiment and valuation.
8 May
INmune Bio (INMB) released Q1 2026 earnings call transcript detailing quarterly financial results, clinical trial updates, and management guidance on pipeline progress and commercialization plans. Q1 2026 earnings transcript discloses financial performance, pipeline advancements, and strategic outlook capable of significantly shifting INMB's market trajectory and investor confidence.
INmune Bio, Inc. (INMB) released Q1 2026 earnings call summary covering financial results, operational updates, and future outlook. Quarterly earnings summary impacts financial performance and investor sentiment moderately without transformative shifts.
7 May
INmune Bio Inc. announced first quarter 2026 financial results and provided a business update. Quarterly results announcements typically influence financial performance and investor sentiment moderately.
5 May
INmune Bio and Anthony Nolan announce strategic expansion of CORDStrom™ MSC platform collaboration to target RDEB, oncology, and inflammatory diseases. Expansion of collaboration into RDEB, oncology, and inflammatory diseases bolsters INMB's pipeline and competitive positioning in key therapeutic areas.
30 Apr
INmune Bio Inc. will report first quarter 2026 financial results and provide a corporate update on May 7th. Scheduled earnings report and corporate update may noticeably influence financial performance and investor sentiment.
16 Apr
INmune Bio Inc. announces new preclinical data at AACR 2026 showing INB03 (XPro1595) overcomes resistance and reduces metastases in HER2-positive breast cancer models. Preclinical efficacy in resistant HER2-positive breast cancer bolsters INMB's pipeline but impact is moderated by need for clinical validation.
1 Apr
INmune Bio (NASDAQ:INMB) faces pressure to manage its limited cash reserves prudently amid ongoing operations and development needs. Cash conservation warnings highlight potential constraints on INmune Bio's financial runway and near-term performance.
31 Mar
INmune Bio, Inc. detailed Q4 2025 financial results, pipeline progress in oncology and Alzheimer's treatments, clinical trial updates, and 2026 guidance during earnings call. Earnings results and pipeline advancements signal major shifts in financial trajectory and investor confidence.
30 Mar
INmune Bio Inc (INMB) Q4 2025 earnings call highlighted strategic advances in clinical programs and partnerships amid financial challenges including cash burn and need for funding. Strategic clinical and partnership progress signals major pipeline momentum despite financial strains that could reshape investor outlook and stock trajectory.
INmune Bio Inc. (INMB) announced its 2025 results and provided a business update. 2025 results and business updates signal major financial and strategic developments critical to INMB's biotech pipeline and investor outlook.
19 Mar
INmune Bio’s MINDFuL Trial featured at AD/PD 2026 Plenary as successful example of clinical trials targeting inflammation in early Alzheimer’s Disease. Plenary feature at premier AD/PD conference validates INMB's inflammation-targeting strategy in Alzheimer's, enhancing investor sentiment and trial credibility.
23 Feb
INmune Bio, Inc. (INMB) will detail its XPro1595 registrational strategy in an upcoming Alzheimer’s webinar. Detailing registrational strategy for Alzheimer’s candidate XPro1595 represents a major strategic milestone likely to boost investor sentiment and stock performance.
19 Feb
INmune Bio, Inc. (INMB) announces an upcoming webinar to present new clinical data on CORDStrom™ for Recessive Dystrophic Epidermolysis Bullosa (RDEB). Upcoming presentation of new clinical data on CORDStrom™ for RDEB may moderately influence investor sentiment and clinical development progress.